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Summary 
Late-onset multiple carboxylase deficiency is characterized clinically by skin rash, 
alopecia, seizures and ataxia and occasionally by candidiasis and developmental 
delay. Biochemically, these individuals exhibit findings consistent with a combined 
deficiency of the biotin-dependent carboxylases. We have found that the activity of 
the enzyme biotinidase is also deficient in the sera of five affected children (0 to 3% 
of mean control activity, 5.80 & 0.89 nmol . min- ’ . ml- ’ serum), and believe that it 
represents the primary biochemical defect in this disease. Biotinidase catalyzes the 
removal of biotin from the c-amino group of lysine, through which biotin is 
covalently bound to the four known human carboxylases, thereby regenerating 
biotin for reutilization. The deficient activity in our patients was not due to an 
inhibitor, particularly biotin. It is also not a consequence of feedback control in 
affected individuals under treatment with pharmacologic doses of biotin. The 
biotinidase activities of the parents of those children who were available for study 
were intermediate between deficient and normal values (46% to 65% of mean normal 
activity). Children lacking biotinidase activity are unable to recycle biotin, and are 
thus entirely dependent upon exogenous biotin to prevent deficiency. Our findings 
indicate that the primary biochemical defect in late-onset multiple carboxylase 
deficiency is in biotinidase activity which is inherited as an autosomal recessive trait. 
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There are two types of multiple carboxylase deficiency (MCD), the neonatal form 
in which the usual presenting symptoms are vomiting, lethargy and hypotonia, and 
the late-onset or juvenile form which is characterized by skin rash, conjunctivitis, 
alopecia, ataxia and occasionally by candidiasis and developmental delay [ 1,2]. 
Biochemically, patients with both disorders may exhibit ketolactic acidosis and 
organic aciduria caused by deficient activities of the biotin-dependent enzymes, 
propionyl CoA carboxylase, pyruvate carboxylase and ~-methylcrotonyl CoA 
carboxylase [2]. Leukocyte enzyme activities are usually deficient prior to the 
administration of pharmacologic doses of biotin but become normal or nearly 
normal after treatment. The two disorders can be distinguished, however, by 
demonstrating carboxylase deficiency in fibroblasts in the neonatal form when the 
fibroblasts are grown in medium containing low concentrations of biotin, and 
normal enzyme activities under similar conditions in fibroblasts from the late-onset 
form. In addition, patients with the late-onset form frequently have lower than 
normal serum concentrations of biotin, whereas the serum biotin concentrations are 
normal in the neonatal variant. The neonatal disorder has recently been shown to 
result from a deficiency in the activity of holocarboxylase synthetase, the enzyme 
that covalently links biotin to the various apocarboxylases forming active enzymes 
[3,4]. Since cells from patients with the late-onset form of the disease have normal 
holocarboxylase synthetase activity [5], it has been assumed that this condition 
results from a defect in either the renal or intestinal transport of biotin and studies 
from several laboratories have therefore focused on the intestinal absorption and 
renal excretion of the vitamin [6-S]. However, the hepatic biotin pool is very large in 
comparison to the small amount of biotin which is normally absorbed from the diet 
or intestinal flora each day [9,10]. We therefore sought to test the alternative 
hypothesis that late-onset MCD results from an abnormality in biotin metabolism or 
turnover rather than a primary defect in biotin transport. The enzyme biotinidase 
(EC 3.5.1.12) is of critical importance in biotin metabolism; it catalyzes the removal 
of biotin from biocytin, r-N-biotinyl-lysine, which is a product of carboxylase 
degradation [11,12]. Significant biotinidase activity is found normally in liver, 
kidney, intestines and serum [ 131. When we measured the activities of biotinidase in 
the serum of patients with late-onset MCD, we found that the activity of the enzyme 
was almost undetectable. 
Materials and methods 
Biotinidase activity was determined colo~met~ca~y by measuring p-amino- 
benzoate liberation from N-biotinyl-p-aminobenzoate. N-Biotinyl-p-aminobenzoate 
was prepared by a modification of the method of Bayer and Wilchek [ 141. Biotin-N- 
hydroxysuccinimide ester (1 mmol; Sigma, St. Louis, MO, USA) suspended in 3 ml 
of dimethylforma~de was added to I mmol of ~-a~nobenzoate (Baker Chem. Co., 
Phillipsburg, NJ, USA) dissolved in 4 ml of 0.2 mol/l NaHCO, at O”C, adjusted to 
pH 8.0 and reacted for 3 h. The solvent was evaporated under reduced pressure and 
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the ~-biotinyl-p-a~obe~ate precipitated by the addition of 5 ml of 10% citric 
acid. The precipitate was filtered and washed twice with water. Crystals obtained 
after air drying yielded 88 mg of product. Chemical analysis of the product revealed: 
melting point = 296’C, C = 52.9% H = 6.1% N = 11.3% and S = 5.9% (Atlantic 
Microlab, Inc., Atlanta, GA, USA); expected (C,,H,,O,N$, M, 363): melting point 
295-297OC 1151, C = 56% H = 5.88, N = 11.5% S = 8.8%. Cellulose thin layer 
c~omato~aphy (Eastman chromagram sheets 6064, Rochester, NY, USA) of our 
product revealed only single spots after development with 4-dimethylaminocinnam- 
aldehyde [ 161 using two different solvent systems (R, = 0.55 in isopropanol/am- 
mania/water: 80 : 5 : 15, by vol., and R, = 0.70 in methanol/isoamyl alcohol/ben- 
zene/water/ammonia: 35 : 17.5 : 35 : 10 : 2.5, by vol.). No free p-aminobenzoate or 
any other ~n~~omatic compound was detectable in our product using the 
reaction described below. 
Fasting human serum was obtained from eight normal donors, five children with 
clinical and biochemical features consistent with late-onset MCD (four males and 
one female) of four families, and six of their parents available for study. Serum was 
also obtained from a patient with documented holocarboxylase synthetase deficiency 
[5,17] and from a patient who developed biotin deficiency due to parenteral 
hyperalimentation which lacked biotin and who has been treated approximately 3 
years with 10 mg of biotin daily [ 181. Urine to be examined for the presence of 
biocytin was also obtained from several of the affected late-onset MCD patients. 
Biotinidase activity was determined with slight modifications of the method of 
Knappe et al [15]_ After a preincubation of 15 min at 37’C, the enzyme assay was 
initiated by the addition of 0.1 ml serum to 1.9 ml of a mixture containing 200 pm01 
potassium phosphate buffer, pH 6.0,20 pmol EDTA, 0.5 mg serum albumin, and 0.3 
pm01 N-biotinyl-p-aminobenzoate bringing the final volume to 2 ml (0.3 ml of 
diluted serum was used in experiments to determine activity as a function of the 
amount of enzyme). The mixture was incubated for 30 min at 37’C and the reaction 
was terminated by the addition of 0.2 ml of 30% trichloroacetic acid. The mixture 
was then centrifuged at 2000 X g for 10 min. 1.5 ml of the supematant was added to 
0.5 ml water. At room temperature, and at 3-min intervals, 0.2 ml of 0.1% sodium 
nitrite (made fresh daily), 0.2 ml of 0.5% ammonium sulfamate and 0.2 ml of 0.1% 
N-1-naphthyl ethylenediamine hydro&loride are added in succession and allowed to 
incubate for 10 min before measuring absorbance at 546 nm. Biotinidase activity is 
expressed as nmol of p-~nobe~ate liberated per min per ml serum. No dif- 
ferences in biotinidase activity were noted between serum frozen immediately and 
that stored at -70°C for up to 1 month. 
Amino acid analyses of serum and urine were performed on a Durram amino acid 
analyzer using a Dowex OC-4A column and a sodium citrate buffer system. Amino 
acids were detected using ~phthalaldehyde (Fluropa; Pickering Products 
Mountainview, CA) (100 to 1000 times more sensitive than ninhydrin) at the 
excitation and emission wavelengths, 360 run and 465 mu, respectively. 
Biotin was purchased from Sigma (St. Louis, MO, USA). Biocytin was kindly 
supplied by Merck, Sharp and Dohme Research Laboratories (Rahway, NJ, USA), 
and was also purchased from Sigma (St. Louis, MO). Avidin-sepharose (ultrogel) 
was purchased from LKB (Bromma, Sweden). 
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Results 
Biotinidase activity was measured in serum and in fibrobiast extracts using the 
colo~metric assay. Biotinidase activity was linear up to 0.3 ml of serum (Fig. IA). 
Biotinidase activity in 0.1 ml of human serum was also found to be linear for up to 
40 min (Fig. 1B). Biotinidase activity in fasting human serum from 18 children and 
adults was determined to be 5.80 nmol - min- ’ . ml-’ serum (Table I). The apparent 
K, of N-biotinyl-p-aminobenzoate for biotinidase is 10 pmol/l, which is in agree- 
ment with previously published values [ 151. Fibroblast extracts from normal individ- 
uals incubated for several hours showed very little detectable activity by the 
calorimetric assay. 
Biotinidase activity in the sera of all five of the children with the clinical features 
of late-onset MCD was almost undetectable (Table I). No increase in activity was 
found after increasing the concentration of substrate to 60 mmol/l. The biotinidase 
activities of the serum from the six parents who were available for study were all 
intermediate between that of the affected children and normal controls (mean = 3.08 
& 0.48 nmol . min- ’ * ml- ’ serum) with a mean percentage of mean control activity 
of 53% (Table I). Biotinidase activity in one patient with holocarboxylase synthetase 
deficiency was normal (Table I). 
All of the affected children were receiving pharmacologic doses of biotin at the 
time the sera was collected. Althou~ biotin has been shown to be a competitive 
inhibitor of biotinidase for biocytin we did not expect the biotin in the serum to 
interfere with our biotinidase assay because the concentration of N-biotinyl-p- 
aminobenzoate is 1000 times the highest molar concentration of biotin reported in a 





VOLUME OF SERUM ($1 INCUBATION TIME (mm) 
Fig. 1. Biotinidase activity measured in serum as a function of volume of serum and time of incubation. 
A. Biotinidase activity ( p-aminobenzoate liberated per min) was measured calorimetrically using various 
incubation volumes of normal serum made up to 300 pf with 50 mmol/i potassium phosphate buffer pH 
6.0. The reaction was incubated for 30 min at 37*C. B. Biotinidase activity ( p-aminobenzoate liberated 
per ml serum) was measured for various times of incubation (min) using 0.1 ml of normal serum. 
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TABLE I 
Serum biotinidase activity in various individuals 
Subject Biotinidase activity 
(nmol .min- ‘.ml- ’ serum) 
Mean control activity (%) 
Proband I 0.16 * 3 
Proband 2 0.00 0 
Proband 3 0.00 0 
Proband 4 0.08 0 
Proband 5 0.18 3 
Mother (proband I) 2.64 46 
Mother (proband 2 and 3) 3.36 sf 
Father (proband 2 and 3) 3.80 65 
Mother (proband 4) 2.70 47 
Father (proband 4) 3.33 57 
Mother (proband 5) 2.68 46 
Patient with holocarboxylase 
synthetase deficiency 
6.73 116 
Patient with biotin 
deficiency receiving 
IO mg of biotin/day 
6.26 108 






* All enzyme determinations were performed in duplicate and several values were the mean activities of 
two separate serum samples. 
biotinidase is 10 to 50 times higher than the K, of the substrate for biotinidase 
[ 13,151. Nevertheless, we examined the effect of high concentrations of biotin on 
biotinidase activity. Biotin, 1 pg/ml, was added to normal serum and incubated for 
15 min at 37*C. As expected, no decrease in activity was observed at this biotin 
concentration because of the great excess of artificial substrate to biotin used in the 
assay. In a separate study, sera from the affected children were pretreated with 
avidin-sepharose for 15 min at 37’C to remove free biotin. The matrix was 
sedimented by ~nt~fugation at 1000 X g for 2 min and the serum removed and 
assayed for biotinidase activity. Under these conditions there was no increase in 
biotinidase activity in these samples. There was no change in biotinidase activity in 
normal serum treated similarly. Biotinidase activity was also normal in the serum of 
a patient who became biotin deficient while receiving parenteral h~er~mentation 
(Table I). These findings demonstrate that the administration of pharmacologic 
doses of biotin does not result in decreased serum biotinidase activity. 
Mixing experiments using proportional volumes of sera from affected children 
and controls resulted in the expected percentages of control activity, thus providing 
no evidence for the presence of an inhibitor of biotinidase in the affected sera. 
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TABLE II 
Effect of mixing various proportions of serum from an affected individual and a normal individual 
Normal serum (S) Serum from affected 
individual (%) 
Observed biotinidase Expected biotinidase 
activity activity 
(nmol.min-‘.rnl-‘) (nmol~min~‘~ml~‘) 
100 0 5.00 5.00 
75 25 4.02 3.75 
50 50 2.80 2.50 
25 75 1.40 1.25 
0 100 0.00 0.00 
Results of a representative mixing experiment are shown in Table II. In addition, 
mixing the sera of the various affected children (1 : 1, v/v) did not result in 
complementation. 
We examined the serum and urine of the affected patients and several normal 
individuals for the presence of biocytin by amino acid analysis. Since biocytin is an 
amino acid it reacts with fluorescent reagents specific for amino groups and can 
readily be detected by fluorometry. The retention time of biocytin was determined 
by running pure samples of biocytin and by running amino acid standards and 
normal serum with biocytin added. Biocytin eluted just after phenylalanine. The 
analysis of sera and urine from affected patients did not reveal any detectable 
biocytin at the limits of our sensitivity (2.0 nmol/ml), 
Discussion 
We have demonstrated almost undetectable biotinidase activity in the sera of five 
patients who had typical findings of late-onset MCD. Biotinidase activity was 
intermediate between deficient and normal values in the sera of all of the parents 
studied, with no overlap in the range of activities between the two groups. Mixing 
studies using sera from normal and affected individuals provided evidence that the 
observed deficiency did not result from an inhibitor in the serum of affected 
children. Similarly, high concentrations of biotin failed to inhibit the enzyme activity 
of normal subjects, essentially excluding a feedback control of serum biotinidase 
activity. These findings and the fact that both males and females are affected, are all 
consistent with the assumption that biotinidase deficiency is inherited as an auto- 
somal recessive trait. 
Our finding of biotinidase deficiency in patients with late-onset MCD suggests 
that the clinical and biochemical features of this disorder can best be understood as 
a defect in biotin metabolism. Biotinidase appears to be necessary for the normal 
recycling of biotin that has been incorporated into the various carboxylases and may 
represent an evolutionary adaptation by eukaryotic organisms to the loss of their 
ability to synthesize biotin. In normal individuals, the presence of biotinidase 
activity greatly reduces the extent of their dependency on exogenous biotin. In 
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affected patients with late-onset MCD, the biotin salvage pathway is blocked and 
high concentrations of dietary biotin are therefore required to prevent symptoms of 
vitamin deficiency. Normally, in tissues with biotinidase activity, biotin is promptly 
liberated and made available for reutilization as soon as the carboxylases are 
degraded sufficiently to allow the enzyme to cleave biotin from the c-amino group of 
lysine. Patients with biotinidase deficiency are unable to cleave biotin from the 
partially degraded carboxylases resulting in continued digestion by proteases and 
peptidases to yield biocytin which cannot be further catabolized. Unfortunately, we 
were unable to detect biocytin in the plasma or urine of affected individuals. This is 
not surprising because of the limited sensitivity of the amino acid analyses even if all 
the measurable ‘biotin’ in serum or urine is actually biocytin. 
In normal individuals, the intracellular regeneration of free biotin can occur in 
any tissue that contains biotinidase. Small quantities of biocytin may be transported 
out into the blood from tissues that lack the enzyme and are therefore dependent on 
biotin transport to meet their biosynthetic and metabolic needs. Further evidence for 
biotin recycling is provided by a study of the increase in carboxylase activities in 
peripheral blood leukocytes that occurs in normal individuals following the adminis- 
tration of pharmacologic doses of biotin [20]. The increase in enzyme activity begins 
almost immediately and reaches maximal levels in 7 to 10 days; however, the 
carboxylase activities return to pretreatment values after 5 to 6 weeks following 
discontinuation of the supplemental biotin intake. In patients with biotinidase 
deficiency, biocytin probably accumulates gradually as the available biotin pool is 
depleted, eventually creating a biotin-deficiency state in these children. 
Studies in animals and man have shown that biotin deficiency can occur after the 
administration of avidin or eggs containing avidin thereby lowering the absorbable 
biotin available in the diet, or from the intestinal flora [lo]. This deficiency state 
requires 6 to 8 weeks to achieve in rats and 8 to 10 weeks in man [lo]. Presumably 
the symptoms of biotin deficiency would occur much more rapidly in a patient with 
late-onset MCD following the complete removal of exogenous biotin. Biotin de- 
ficiency can also be produced by completely restricting biotin in the diet as seen in 
patients treated by biotin-deficient parenteral alimentation [ 1821,221. In these 
conditions decreased dietary biotin is ‘insufficient to replace the biotin, in the form 
of biocytin, which is slowly lost from the various tissues into the blood and is 
subsequently excreted in the urine. Children with biotinidase deficiency have biotin 
dependency, requiring continual replacement of their rapidly depleted tissue stores. 
The estimated hepatic biotin pool for a l-year-old child is approximately 120 pg 
biotin [9], whereas the pool size for an adult is about 675 pg. In contrast, the 
estimated total blood biotin contents are only 0.95 pg and 2.4 pg, respectively. These 
126-fold and 280-fold higher hepatic to plasma biotin pools indicate that biotin 
turnover is essential for normal biotin utilization. A continuous decrease in the 
hepatic biotin pool cannot likely be replaced by the small quantities of biotin 
absorbed from that in the normal diet. Supplementing these patients with pharmaco- 
logic doses of the vitamin rapidly increases their available biotin, and causes rapid 
clinical improvement. 
There are very definite differences between the neonatal-onset form of MCD due 
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to holocarboxylase synthetase deficiency and late-onset MCD. The latter is char- 
acterized by alopecia, ataxia, candidiasis, skin rash and conjunctivitis. Some of these 
features are common to !h ose seen in the biotin-deficient state but others could 
result from a toxic effect of biocytin by, as yet, unknown mechanisms, possibly 
similar to those occurring in storage diseases. 
The carboxylase deficiencies seen in this disease may be the result of the 
biotin-deficient state, or alternatively, biocytin may competitively inhibit holo- 
carboxylase synthetase, as shown by the decreased incorporation of 14C-biotin into 
apocarboxylase in the presence of biocytin [23]. 
The serum biotin concentrations in individuals with late-onset MCD have been 
reported as normal or slightly below the normal range [2]. The biotin concentration 
in one of our patients was, in fact, slightly above the normal range. Since the 
methods for measuring biotin with avidin fail to discriminate between biotin and 
biocytin [9,24], it is not surprising that symptomatic children may have normal or 
nearly normal ‘ biotin’ concentrations. Examining these same sera by microbiological 
bioassays using bacteria that grow in the presence of biotin, but not biocytin [ 121, 
may reveal that these patients are actually biotin deficient. 
Several studies, examining the rise in serum concentration of biotin following the 
administration of varying quantities of oral biotin to patients with late-onset MCD, 
have suggested the presence of an abnormality in the intestinal absorption of biotin 
[6,7]. In vitro studies of intestinal biotin uptake in hamster have demonstrated that 
biocytin is a potent competitive inhibitor of biotin absorption [25]. Other reports 
have described abnormal urinary excretion of biotin in patients with late-onset 
MCD [8]. Since there is normally considerable biotinidase activity in the kidney. it 
seems plausible to suggest that in biotinidase deficiency abnormalities in renal 
transport may also result from competitive inhibition of normal biotin transport by 
the elevated concentrations of endogenous biocytin. In patients with biotinidase 
deficiency on a normal dietary biotin intake, the ratio of biocytin to biotin may 
gradually increase to a critical level at which biocytin can competitively inhibit these 
various transport pathways. 
Although other causes of late-onset MCD are possible, our results indicate that 
one, if not the only cause, is biotinidase deficiency. 
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